The United States retains its lead over China in biotechnology, but that lead is narrowing, according to the latest Biotech Scorecard from the Special Competitive Studies Project (SCSP), a nonprofit and nonpartisan initiative aimed at strengthening America's long-term competitiveness in artificial intelligence. The report, which evaluates the global biotech competition, warns that China could overtake the U.S. by 2030, bolstered by two decades of deliberate national strategy now producing results.
The SCSP's Tech Scorecard methodology uses a five-point analysis covering Innovation Leadership, Market Ecosystem, Talent Pipeline, Industrial Capacity, and National Leverage. While the U.S. leads in Innovation Leadership, Market Ecosystem, and Talent Pipeline, China appears ahead in Industrial Capacity and National Leverage. The report focuses on the biopharmaceuticals sector as an example of China's acceleration in those two areas.
Most U.S. government funding for biotechnology goes to basic research, and a lack of urgency persists in expanding support for commercialization of drug products. By contrast, China actively supports biotech startups through the process of acquiring capital to build pilot capacity, scale up production, and reach markets without waiting for a definitive return on these expanded investments. This strategy includes preferential taxation, below-market lending, and direct subsidies, while the U.S. tends to leave this aspect of development to the private sector.
The American position is described as "a return on research investments made decades ago, sustained by a capital market that rewards its strongest performers," according to SCSP's analysts. The authors emphasize that approval timelines for drugs entering clinical trials and going to domestic markets are driven by government policy and can help accelerate or slow down the pipeline of innovation.
Looking ahead, as artificial intelligence allows scientists to predict molecular activity, the expensive early stages of drug discovery will likely decrease, and competitive advantage will shift to testing, manufacturing, and commercializing a promising drug candidate. "Whether the United States retains its edge depends both on model quality and how quickly it can move a computationally generated candidate through trials, approval, and manufacture before a competitor improves on it," the report states.
This matters for readers, industry, and the broader economy because biotechnology underpins drug development, public health, and national security. A shift in leadership could affect everything from access to medicines to supply chain resilience and economic growth. The SCSP scorecard underscores that the battle for biotech leadership is not won in a single field but across supply chains, manufacturing capacity, data holdings, and regulatory speed. To read the full report and learn more, visit scsp.ai.
